These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 36768213)

  • 1. Antitumor Effect of Korean Red Ginseng through Blockade of PD-1/PD-L1 Interaction in a Humanized PD-L1 Knock-In MC38 Cancer Mouse Model.
    Lee EJ; Yang JH; Yang HJ; Cho CK; Choi JG; Chung HS
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uncovering the colorectal cancer immunotherapeutic potential: Evening primrose (Oenothera biennis) root extract and its active compound oenothein B targeting the PD-1/PD-L1 blockade.
    Lee EJ; Kim YS; Kim JH; Woo KW; Park YH; Ha JH; Li W; Kim TI; An BK; Cho HW; Han JH; Choi JG; Chung HS
    Phytomedicine; 2024 Mar; 125():155370. PubMed ID: 38266440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmented Antitumor Effect of Unripe
    Lee EJ; Yang JH; Choi JG; Chung HS
    Cells; 2022 Sep; 11(18):. PubMed ID: 36139451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model.
    Lee EJ; Kim JH; Kim TI; Kim YJ; Pak ME; Jeon CH; Park YJ; Li W; Kim YS; Choi JG; Chung HS
    Front Immunol; 2021; 12():737076. PubMed ID: 34659228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8
    Huang MY; Chen YC; Lyu WY; He XY; Ye ZH; Huang CY; He XL; Chen X; Chen X; Zhang B; Kai G; Zhang X; Li T; Huang M; Lu JJ
    Pharmacol Res; 2023 Dec; 198():106988. PubMed ID: 37984507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
    Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
    Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.
    Cheng LS; Zhu M; Gao Y; Liu WT; Yin W; Zhou P; Zhu Z; Niu L; Zeng X; Zhang D; Fang Q; Wang F; Zhao Q; Zhang Y; Shen G
    Cell Mol Biol Lett; 2023 May; 28(1):47. PubMed ID: 37259060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer Effect of
    Choi JG; Kim YS; Kim JH; Kim TI; Li W; Oh TW; Jeon CH; Kim SJ; Chung HS
    Front Immunol; 2020; 11():598556. PubMed ID: 33224152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chlorin e6-associated photodynamic therapy enhances abscopal antitumor effects via inhibition of PD-1/PD-L1 immune checkpoint.
    Gurung P; Lim J; Shrestha R; Kim YW
    Sci Rep; 2023 Mar; 13(1):4647. PubMed ID: 36944686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy.
    Jin S; Wang H; Li Y; Yang J; Li B; Shi P; Zhang X; Zhou X; Zhou X; Niu X; Wu M; Wu Y; Zhai W; Qi Y; Gao Y; Zhao W
    Cell Commun Signal; 2024 Mar; 22(1):173. PubMed ID: 38462636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy.
    Zhai W; Zhou X; Zhai M; Li W; Ran Y; Sun Y; Du J; Zhao W; Xing L; Qi Y; Gao Y
    Sci China Life Sci; 2021 Apr; 64(4):548-562. PubMed ID: 32737851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.
    Huang A; Peng D; Guo H; Ben Y; Zuo X; Wu F; Yang X; Teng F; Li Z; Qian X; Qin FX
    Sci Rep; 2017 Feb; 7():42687. PubMed ID: 28202921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-Cell RNA Sequencing Reveals Immuno-Oncology Characteristics of Tumor-Infiltrating T Lymphocytes in Photodynamic Therapy-Treated Colorectal Cancer Mouse Model.
    Lee EJ; Choi JG; Han JH; Kim YW; Lim J; Chung HS
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.
    Peper-Gabriel JK; Pavlidou M; Pattarini L; Morales-Kastresana A; Jaquin TJ; Gallou C; Hansbauer EM; Richter M; Lelievre H; Scholer-Dahirel A; Bossenmaier B; Sancerne C; Riviere M; Grandclaudon M; Zettl M; Bel Aiba RS; Rothe C; Blanc V; Olwill SA
    Clin Cancer Res; 2022 Aug; 28(15):3387-3399. PubMed ID: 35121624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity.
    Jiang H; Ni H; Zhang P; Guo X; Wu M; Shen H; Wang J; Wu W; Wu Z; Ding J; Tang R; Zhou S; Chen B; Yu M; Jing H; Liu J
    Oncoimmunology; 2021; 10(1):1943180. PubMed ID: 34239776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination treatment with 17β-estradiol and anti-PD-L1 suppresses MC38 tumor growth by reducing PD-L1 expression and enhancing M1 macrophage population in MC38 colon tumor model.
    Song CH; Kim N; Nam RH; Choi SI; Jang JY; Kim JW; Na HY; Lee HN
    Cancer Lett; 2022 Sep; 543():215780. PubMed ID: 35690286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity.
    Juneja VR; McGuire KA; Manguso RT; LaFleur MW; Collins N; Haining WN; Freeman GJ; Sharpe AH
    J Exp Med; 2017 Apr; 214(4):895-904. PubMed ID: 28302645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor perfusion enhancement by ultrasound stimulated microbubbles potentiates PD-L1 blockade of MC38 colon cancer in mice.
    Li N; Tang J; Yang J; Zhu B; Wang X; Luo Y; Yang H; Jang F; Zou J; Liu Z; Wang Z
    Cancer Lett; 2021 Feb; 498():121-129. PubMed ID: 33129956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.